Menu Search
Equities

Devyser Diagnostics AB

DVYSR:STO

Devyser Diagnostics AB

Actions
  • Price (SEK)131.00
  • Today's Change6.50 / 5.22%
  • Shares traded106.58k
  • 1 Year change+93.22%
  • Beta--
Data delayed at least 15 minutes, as of Sep 23 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The 4 analysts offering 12 month price targets for Devyser Diagnostics AB have a median target of 130.00, with a high estimate of 192.00 and a low estimate of 100.00. The median estimate represents a -0.76% decrease from the last price of 131.00.
High46.6%192.00
Med-0.8%130.00
Low-23.7%100.00

Earnings history & estimates in SEK

On Jul 23, 2024, Devyser Diagnostics AB reported 2nd quarter 2024 losses of -1.41 per share.
The next earnings announcement is expected on Oct 30, 2024.
Average growth rate-34.77%
Devyser Diagnostics AB reported annual 2023 losses of -3.31 per share on Feb 20, 2024.
Average growth rate-35.37%
More ▼

Revenue history & estimates in SEK

Devyser Diagnostics AB had 2nd quarter 2024 revenues of 53.20m. This bettered the 53.00m consensus of the 2 analysts covering the company. This was 34.68% above the prior year's 2nd quarter results.
Average growth rate+9.42%
Devyser Diagnostics AB had revenues for the full year 2023 of 169.30m. This was 33.73% above the prior year's results.
Average growth rate+34.56%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.